CD11b Antibody, anti-mouse, REAfinity™
Synonyms: integrin αM, Mac-1 α, Integrin alpha-M, CR3A
RECOMBINANT EXTENDED VALIDATION
Bioz Star96/100 Bioz rating
235 Citations25 Images
Clone:
REA592 | M1/70.15.11.5
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC, MICS, IF, IHC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:

Related products for CD11b Antibody, anti-mouse, REAfinity™

Flow cytometry applications
APC
APC-Vio 770
Biotin
PE
PE-Vio 615
PE-Vio 770
PerCP-Vio 700
Vio Bright FITC
VioBlue
VioGreen
Recommended dilution:
1:50
Remark:
Cells should be stained prior to fixation, if formaldehyde is used as a fixative.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-113-802
Description:
Splenocytes from BALB/c mice were stained with CD11b antibodies or with the corresponding REA Control antibodies (left images). Flow cytometry was performed using the MACSQuant® Analyzer. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence.

Application imageView details view details

Application imageView details view details
MICS (MACSima Imaging Cyclic Staining) applications
APC
PE
Fixation:
frozen – PFA
Species tested:
mouse
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC
Conjugate:
APC
Used products:
130-113-802
Testing grade:
Fixation:
frozen – Acetone
Species tested:
mouse
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC
Conjugate:
APC
Used products:
130-113-802
Testing grade:
Extended validation for CD11b Antibody, anti-mouse, REAfinity™
Specificity
Epitope competition assay

In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.

Other clones
Overlap in epitope recognition with REA592
M1/70
high
M1/70.15.11.5
high
5C6
partial
REAL113
high

Cells were incubated with an excess of purified unconjugated CD11b (REA592) antibody followed by staining with fluorochrome-conjugated antibodies from other known clones targeting the same antigen. Fluorescence intensity was then used to assess epitope overlap: a minimal or absent signal indicated high epitope overlap, an intermediate signal suggested partial overlap, and a strong signal reflected low overlap.

Sensitivity
Performance comparison

Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.

Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image

Flow cytometric comparison of different clones for CD11b. C57BL/6 cells were stained with CD11b antibodies and plotted against the side scatter. As a control, CD11b antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Fixation data

To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.

No fixation
Extended-Validation detailed information image
Post fixation
Extended-Validation detailed information image

Comparison of staining pattern on non-fixed and fixed cells using CD11b (REA592). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for CD11b Antibody, anti-mouse, REAfinity™
Overview

Clone REA592 recognizes the mouse CD11b antigen (Mac-1 α; integrin αM chain), which is part of the CD11b/CD18 heterodimer (Mac-1 α, Mβ2 integrin), also known as the C3 complement receptor. It functions as a receptor for complement (C3bi), fibrinogen, or clotting factor X. CD11b is expressed on monocytes, macrophages, and microglia. To a lower extent it is expressed on granulocytes, NK cells, CD5+ B-1 cells, and subsets of dendritic cells. Clone REA592 recognizes also the non-human primate and human CD11b antigen.

Additional information: Clone REA592 displays negligible binding to Fc receptors.

Alternative names

integrin αM, Mac-1 α, Integrin alpha-M, CR3A

Detailed product information

Technical specifications

Clone
REA592
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody, human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human, mouse, non-human primate
Cross-reactivity
rhesus monkey (Macaca mulatta), cynomolgus monkey (Macaca fascicularis)
Antigen
CD11b
Molecular mass of antigen [kDa]
126, same molecular weight for human and mouse/rat
Distribution of antigen
NK cells, microglia, lymphocytes, monocytes, macrophages
Entrez Gene ID
RRID
AB_2726050, AB_2726324, AB_2751173, AB_2726325, AB_2726326, AB_2726049, AB_2819369, AB_2733498, AB_2751172, AB_2726327, AB_2751107, AB_2751174, AB_2733499, AB_2726328

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for CD11b Antibody, anti-mouse, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

You have previously chosen International as your location.
What do you want to do?